1 | P a g e

SUMMER TRAINING REPORT

ON
MARKET ANALYSIS OF THE REPIRATORY AND
NEPHRO SEGMENTS IN INDIAN PHARMACETICAL
INDUSTRY
(COMPLETED IN MANKIND PHARMA)
(Submitted in Partial Fulfillment of the requirement of Masters
of business administration)


Submitted to: Submitted by:
Dr. Meghna Sharma Ishneet walia
A1802012045
MBA-IB
(2
nd
year, third semester)



Submitted to:
AMITY UNIVERSITY,Noida,Uttar Pradesh

2 | P a g e










ACKNOWLEDGEMENT









3 | P a g e

ACKNOWLEDGEMENT

No project is done without valuable assistance.It gives me great pleasure in acknowledging the
invaluable assistance expended to me by various personalities in the successful completion of this
report.My debts are due to many individuals who provided me with valuable guidance,advice and
useful comments that helped me in the successful completion of this report.As usual the debts can
be only warmly acknowledged but never fully recompensed.

I am thankful to the intire team of MANKIND PHARMA LTD for the support and guidance they
have given me and specially to Mr. SANJAY KAUL, P.M.T head(product management team),
MANKIND PHARMA LTD., Mr. IRFAN AHMAD, SENIOR PRODUCT MANAGER and also
Ms. MEETU MULCHANDANI for their continuous motivation,teachings,encouragement and
firm guidance for the successful completion of this project work for giving me this opportunity to
work with MANKIND.
I would also give my warm acknowledgement to my faculty guide Dr.MEGHNA SHARMA for
her support and continous supervision in the completion the summer training report.






ISHNEET WALIA
A1802012045
SIGNATURE:

_______________________________


4 | P a g e








DECLARATION
CERTIFICATE









5 | P a g e

TABLE OF CONTENTS

OBJECTIVE OF THE STUDY...6
ABSTRACT...7
COMPANY PROFILE.........9
LITERATURE REVIEW...15
INTRODUCTION...18
RESPIRATORY SEGMENT........................................19
NEPHRO SEGMENT...28
RESEARCH METHODOLOGY
RESPIRATORY SEGMENT38
NEPHRO SEGMENT...49
CONCLUSION AND RECOMMENDATIONS..56
REFERENCES59

6 | P a g e

OBJECTIVE OF THE STUDY

Project objective: my objective is to
1. provide mankind company with the information,analysis and suggestions
regarding the respiratory and uro segments for market analysis.
2. to launch a product in the coming years in the above segments as there is
no product as such of the company in these segments with the help of my
information provided.













7 | P a g e









ABSTRACT






8 | P a g e

ABSTRACT

This project is mainly based on the market analysis of the respiratory segments and nephrology
segments in the Indian pharmaceutical industry. The project report mainly explains the meaning of
respiratory and nephrology, their use, the products used under these segments, the molecules which
are at good growth in the pharmaceutical industry under these segments and also the new
molecules which can be launched by the Indian pharmaceutical company MANKIND PHARMA
in the country.
For the detailed analysis of these segments the three main softwares were taught in this regard:
1. IMS HEALTH
2. PRESCIPTION AUDIT
3. AIOCD(All Indian Origin Chemists & Distributors)
In the report the data is collected and analysed with the above software to give an authentic
analysis. Different data was collected and tables were made to make the conclusion easy and in
readable form. The project will further give an idea to the company for launching new product in
the Indian pharma market with the new molecules that will be taken out after the analysis.
A descriptive pattern of research design has been adopted to make the meaning of the report very
clear and authentic. Data description has been made for focused information.









9 | P a g e









COMPANY PROFILE






10 | P a g e

COMPANY PROFILE




MANKIND GROUP OF COMPANIES
A. PHARMACEUTICAL SEGMENT
DIVISION LAUNCH YEAR
MANKIND PHARMA 1995
DISCOVERY MANKIND 2003
LIFESTAR PHARMA 2005
FUTURE MANKIND 2007
MAGNET 2007
LIFESTAR 2 PHARMA 2012
Mankind Pharma ltd. is the 7
th
largest
Pharmaceutical Company of India, was established in
1995 with capital of 50 lakhs and only 20 employees.
now, they are amongst the top 5 fastest growing
Pharmaceutical companies of India with an employee
base of more than 10000 and heading towards a turnover
of 3000 crores. they aspire to aid the community in
leading a healthy life through two parallel objectives:
formulating, developing & commercializing medicines
and delivering affordable & accessible medication that
satisfies urgent medical needs.

Mr. R.C JUNEJA
(CEO AND CHAIRMAN)


11 | P a g e

Our Mission
"To support a healthy & active lifestyle through our broad portfolio of Pharma, OTC & FMCG
products."
Our Vision
"To be amongst the top two pharmaceutical company of India by 2017-18"

B. OTC/FMCG
DIVISION LAUNCH YEAR
SPECIAL MANKIND 2007


C. ANIMAL HEALTHCARE
DIVISION LAUNCH YEAR
VET MANKIND 2007
PET MANKIND 2010

With the thrust of making headway, in 2007 Mankind acquired Magnet Labs Pvt. Ltd. and marked
its marketing presence in antipsychotic segment. In January 2010, Mankind acquired Longifene,
the former brand of UCB Belgium. We are further expanding the horizon of Serving Life in
Vietnam Philippines, Myanmar and other regulated and semi-regulated markets by 2015.
The company has made separate divisions so that it can segregate and equally take control of each
segment to achieve its goal of 3000 crores easily.

12 | P a g e

PRESENCE IN OVERSEAS MARKETS
SRILANKA VIETNAM RWANDA
PHILIPPINES NEPAL

KEY SUCCESS FACTORS
Disciplined sales force and streamlined marketing practices
Brand building with 118 brands in market leadership position
Focused doctor-centric approach
A low attrition rate at half of industry levels
Good presence in OTC market in premium segments like condoms, body spray, pregnancy
test kit, toothbrush and artificial sweetener


INFRASTRUCTURE
Manufacturing units
For proper supply of quality medicines they have fourteen world class manufacturing units, many
of which are USDF and GMP compliant.
Supply chain
To cater to the ever growing market demand, they have operations into the entire length and
breadth of the country. They have a wide distribution network of 6000 stockists, 61 C&F agents
and field force of 8300 medical representatives and managers.
Distribution offices
Mankind has 4 major distribution offices situated in meerut, Ghaziabad, indore and secundrabad.



13 | P a g e

R&D
They have come up with R&D centre in manesar (ncr delhi). The focus areas being:
API development
New drug delivery system
Formulation development
Contract research

MANKIND POPULAR BRANDS




TOP 10 BRANDS FISCAL YEAR 2011-2012, CONSTITUTE 40% OF THE
PORTFOLIO.
SOURCE- COMPANY ACTUALS



0
20
40
60
80
100
120
140
1
W
o
r
t
h

(
C
r
o
r
e
s
)

name of brand
Top 10 brands of mankind
nurokind
mahacef
zenflox
moxikind
gudcef
amlokind
glimstar
cefakind
ranidom
nobel

14 | P a g e

THE TOP TEN BRANDS OF MANKIND PHARMA ARE AS FOLLOWS:

1. NUROKIND
2. MAHACEF
3. ZENFLOX
4. MOXIKIND
5. GUDCEF
6. AMLOKIND
7. GLIMSTAR
8. CEFAKIND
9. RANIDOM
10. NOBEL




SOURCE- IMS HEALTH MARCH 2012


MARKET SHARE
PROGRESSION- TOP 10 COMPANIES
COMPANY
Mar-12 Mar-08
RANK % SHARE RANK % SHARE
ABBOT 1 7.3% 10 2.3%
CIPLA 2 5.0% 2 5.2%
RANBAXY 3 4.6% 3 5.0%
GLAXOSMITHKLINE 4 4.0% 4 4.7%
SUN 5 4.0% 6 3.3%
ZYDUS CADILA 6 3.7% 5 3.7%
MANKIND 7 3.4% 13 2.2%
ALKEM 8 3.3% 7 3.2%
PFIZER 9 3.2% 8 3.0%
LUPIN LTD. 10 2.7% 9 2.6%

15 | P a g e



















LITERATURE REVIEW








16 | P a g e

LITERATURE REVIEW

The softwares used under the project are:
I.M.S health
Prescription audit
AIOCD
These software are used to carry out the analysis for market survey.

IMS Health is a company that provides information, services and technology for the healthcare
industry. IMS Health was founded in 1954 by Bill Frohlich and David Dubow. In 2010, IMS
Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners.
IMS Healths products and services are used by companies to develop commercialization plans and
portfolio strategies, to select patient and physician populations for specific therapies, and to
measure the effectiveness of pharmaceutical marketing and sales resources.
IMS Health uses its own data to produce syndicated reports such as market forecasts and market
intelligence. These predict how a market in a country or therapy area will change over time. This
works through the production of baseline projections of sales and the application of future events to
this baseline to produce a forecast.
This software was used to carry out the moving annual turnover of the molecules the brands and
the company itself in this project report. It was the major part of the report that was taken into
account.
PRESCRIPTION AUDIT is used to carry out the total no. of prescriptions written by a doctor
each day with reference to the molecules used under there prescriptions.
AIOCD Pharmasofttech AWACS Pvt. Ltd. is a pharmaceutical market research company formed
by All Indian Origin Chemists & Distributors Ltd. (AIOCD Ltd) in a joint venture with Trikaal
Mediinfotech Pvt. Ltd.
AIOCD AWACS is a pharmaceutical market research organization that has evolved into an IT
infrastructure player in Pharma Distribution & Retail. With 7 different product offerings and
several in the offing our aim is to cut time and improve accuracy.



17 | P a g e

AWACS in military parlance stands for Airborne Warning And Control System where it cuts
time and improves accuracy of information. AWACS in AIOCD AWACS stands for Advanced
Working, Action & Correction System giving our clients early & accurate information to plan
strategies & win over competition. The underlying philosophy behind each of our product is to
reduce time to information by 50% or more and to significantly improve on accuracy of
information.

























18 | P a g e








INTRODUCTION







19 | P a g e

INTRODUCTION
RESPIRATORY SYSTEM

FUNCTION OF RESPIRATORY SYSTEM
The main function of the respiratory system of the humans is to flow the air into the lungs and to
facilitate the diffusion of oxygen into the blood stream. It receives the waste of CO2 from the
blood and takes it out.
The respiratory system consists of the following parts, divided into the upper and lower
respiratory tracts:





DEFINATION OF RESPIRATORY SYSTEM
Respiratory system is the set of organs which helps in the
take in as well as the exchange of oxygen and carbon
dioxide in between the organism and the existing
environment, in the human body it includes the nasal
cavity, the pharynx, the trachea, the lungs, bronchi and at
last the diagraph. It includes two things:
A. INHALING B. EXHALING
UPPER RESPIRATORY TRACTS
MOUTH,NOSE,NASAL CAVITY
PHARYNX
LARYNX
LOWER RESOIRATORY TRACTS
TRACHEA
BRONCHI
ALVEOLI
DIAGRAPH

20 | P a g e

UPPER RESPIRATORY TRACTS:

MOUTH, NASAL & NASAL CAVITY- IT IS THE FIRST PART OF THE
RESPIRATORY SYSTEM WHOSE FUNCTION IS TO FILTER THE INCOMING AIR
AS WELL AS TO WARM AND MOISTEN IT.

PHARYNX- IN THIS THE THROAT IS DIVIDED INTO THE TRACHEA AND ALSO
THE FOOD PIPE. THE EPIGLOTTIS PREVENTS FOOD FROM ENTERING THE
TRACHEA.

LARYNX- IT IS THE PART WHERE THE SOUND IS MADE OR GENERATED, IT
ALSO PREVENTS THE TRACHEA BY PRODUCING A STRONG COUGH REFLEX
IF BY CHANCE ANY FOOD PARTICLE OR SUBSTANCE PASSES THE
EPIGLOTTIS.


LOWER RESPIRATORY TRACTS:

TRACHEA- THE OTHER NAME OF TRACHEA IS ALSO WINDPIPE, IT IS THE
TUBE WHICH CARRIES THE AIR TO THE LUNGS. IT IS 10-16 CMS IN LENGTH
AND 20-25 MM IN DIAMETER.THE INNER PART OF THE TRACHEA IS COVERED
IN TINY HAIRS CALLED THE CILIA

BRONCHI- THE TRACHEA IS DIVIDED INTO TWO TUBES, ONE ENTERING
THE LEFT LUNG AND THE OTHER ENTERING THE RIGHT LUNG. THE LEFT
BRONCHI IS NARROWER, LONGER AND HORIZONTAL A COMPARED TO THE
RIGHT.

ALVEOLI- ALVEOLI CONSISTS OF VERY THIN WALLS THAT ALLOWS THE
EXCHANGE OF GASES,CO2 & OXYGEN. IN AN AVERAGE IN AN ADULT LUNG
THERE ARE APPROXIMATELY 3 MILLION ALVEOLI

DIAPHRAGM - DIAPHRAGM IS A BROAD BAND OF MUSCLE THAT IS
LOCATED BENEATH THE LUNGS, ATTACHING THE LOWER RIBS,SPINE AND
THE STERUM FORMING THE BASE OF THE THORACIC CAVITY.

21 | P a g e

RESPIRATORY DISEASES


It includes:
Inflammatory lung disease- this disease is characterized by a high neutrophil count like
asthma, chronic obstructive pulmonary disease, cystic fibrosis, emphysema.
Obstructive lung disease- these are the diseases of the lung which takes place when the
bronchial tubes become narrow which makes it hard to move the air inside and specially out
of the lung.
COPD (chronic obstructive pulmonary disease)- it is the disease where the airways
become damaged causing them to narrow. It is an example of the obstructive lung disease.
Asthma- it is also an example of the obstructive lung disease.
Restrictive lung disease- the other name of the restrictive lung disease is interstial lung
disease which is characterized by the loss of lung compliance, whose causes are incomplete
lung expansion and increased lung stiffness. Eg: respiratory distress syndrome.
Upper respiratory tract disease- the most common disease under this segment is the
common cold. Most infections of particular organs of upper respiratory tract like sinusits,
otis media and laryngitis are also considered upper respiratory tract infections.
Lower respirastory tract disease- the most common disease under this segment is
pneumonia which is a lung infection. Pneumonia is usually caused by bacteria which is
found in western countries. Tuberculosis is an important cause of pneumonia.


It is the term used for the diseases of the respiratory segment.
These include the diseases of the entire respiratory tract and
also the nerves and muscles of breathing. Respiratory disease
also ranges from mild as cough and cold to life threatening
such as bacterial pneumonia.

22 | P a g e

Malignant tumours- it is the other name for cancer in respiratory system, specially lung
cancer which are a major health problem responsible for 15% of all cancer diagnoses and
also 29% of cancer deaths. This tumour is caused through chewing tobacco or smoking
tobacco.
Benign tumours- these diseases are rare of respiratory disease. Its examples are:
pulmonary hamartoma and congenital malformations.
Pulmonary vascular disease- these are the diseases that effect the pulmonary circulation
which is known by a blood clot in a vein which travels through the heart and lodges in the
lungs (thromboembolism).









Asthma fact and fiction
Fiction: Older adults don't get asthma.
Fact: Even though more young people get
asthma, it also affects older adults.
Fiction: Children outgrow asthma or asthma gets
better as you get older.
Fact: Children often don't outgrow asthma. A
child's asthma can get better or worse over time
and some very young children with asthma may
get much better as they (and their lungs) grow.
Fiction: The steroids used in asthma will stunt
growth.

Fact: Large medical studies have shown that
children using inhaled corticosteroids will
eventually reach their normal height, although
there may be very small, temporary delays in
growth initially.

23 | P a g e

TREATMENT OPTIONS FOR RESPIRATORY DISEASES

DRUGS USED FOR COUGH (DRY/PRODUCTIVE)

Cough is a protective reflex, its purpose being expulsion of respiratory secretions or foreign
particles from air passages.
PHARYNGEAL DEMULCENTS: lozenges, cough drops, linctuses containing syrup,
glycerine, liquorice.

EXPECTORANTS: a) bronchial secretion enhancers: sodium or potassium citrate,
potassium iodide, guaiphenesin, balsum of tolu, vasaka,ammonium chloride.
b) mucolytics: bromhexine, ambroxol, acetyl cysteine, carbocisteine

ANTITUSSIVES(COUPGH CENTRE SUPPRESSANTS): a) opioids: codeine,
pholcodeine.
b)nonopioids: noscapine, dextromethorphan, chlophedianol.
c) antihistamines: chlorpheniramine, diphenhydramine, promethazine.

ADJUVANT ANTITUSSIVES: bronchodilators: salbutamol, terbutalin.




24 | P a g e

DRUGS USED FOR ASTHMA

Asthma is characterized by hyperresponsiveness of tracheobronchial smooth muscle to a variety of
stimuli, resulting in narrowing of air tubes, often accompanied by increased secretion, mucosal
edena and mucus plugging. Symptoms include dyspnoea, wheezing, cough and may be limitation
of activity.
BRONCHODILATORS: a) sympathomimetics: salbutamol, terbutaline, bambuterol,
salmeterol, formoterol, ephedrine.
b)methylxanthines: theophylline, aminophylline, choline theophyllinate, hydroxyethyl
theophylline, theophylline ethanolate of piperazine, doxophylline.
c)anticholinergics: ipratropium bromide, tiotropium bromide.

LEUKOTRIENE ANTAGONISTS: montelukast, zafirlukast.

MAST CELL STABILIZERS: sidium cromogycate, ketotifen.

CORTICOSTEROIDS: a)systematic: hydrocortisone, prednisolone and others.
b) inhalational: beclomethasone dipionate, budesonide, fluticasone propionate, flunisolide,
ciclesonide

ANTI-IGE ANTIBODY: omalizuma.
LEUKOTRIENE AND CORTICOSTEROIDS ANTAGONISTS: montelukast, zafirlukast.



25 | P a g e

COMMON RESPIRATORY DISEASE IN INDIA



Most of the disease burden in rural India is due to the respiratory disorders namely asthma,
bronchitis & tuberculosis (TB) and pneumonia. In low resource settings these diseases are
mainly attributed with exposure to indoor pollution, solid-cooking fuels, poor housing, low
nutritional status and sanitary conditions.
Leading cause of death between rural male and female was highlighted in the above Table.
Bronchitis and asthma recorded as leading cause, pneumonia and tuberculosis of the lungs
ranked as one of the five leading causes of deaths in rural India.


26 | P a g e

FDA APPROVED DRUGS IN THERAPEUTIC AREA FOR
RESPIRATORY DISEASES

These are the molecules which are not yet launched in the Indian pharma industry but have been
absorbed by the foreign pharma industry.
These are written year wise from 2013-2008

1. BEDAQUILINE:
This molecule is used in the brand SIRTURO which is owned by janssen therapeutics and
is used for the treatment of multi- drug resistant tuberculosis. It was approved in December
2012.
2. LUCINACTANT:
This molecule is used in the drug SURFAXIN which is owned by discovery laboratories
and is used for the treatment of respiratory distress syndrome in pre mature infants. It was
approved in March 2012.
3. ROFLUMILAST:
This molecule is used in the drug DALIRESP which is owned by forest pharmaceuticals
and is is used for the treatment of chronic obstructive pulmonary disease. And was
approved in February 2011.
4. CEFTAROLINE FOSAMIL:
This molecule is used in the brand TEFLARO which is owned by cerexa and is used for
the treatment of bacterial skin infections and also bacterial pneumonia.it was approved in
November 2010.
5. TREPROSTINIL:
This molecule is used in the product tyvaso which is owned by united therapeutics and is
used for the treatment of pulmonary arterial hypertension and was approved in july 2009
6. CICLESONIDE:
This molecule is used in the product ALVESCO which is owned by nycomed and is used in
maintenance treatment of asthma as prophylactic therapy in adults and adolescents, it is
approved in January 2008.
The following page will indicate the molecules that can be taken into consideration by the
company in order to adopt and also to grow in those molecules.




27 | P a g e


NAME INDICATION CATEGORY
WORTH
(in Cr)

2010 2011 2012 2013
BEDAQUILINE
PULMONARY
TUBERCULOSIS
ANTI-
MICOBACTERIAL
- - 60 280
ROFLUMILAST COPD PDE4 INHIBITOR 30 364 686 -
CEFTAROLINE
FOSAMIL
CAP(COMMUNITY
ACQUIRED , SSTI (SKIN
AND AKIN STRUCTURE
CEPHALOSPORIN 18 131 263 -
TREPROSTINIL
PULMONARY
HYPERTENSION
PROSTACYCLIN
ANALOGUE
901 1432 1940 -

THE ABOVE DATA IS COLLECTED ON THE BASIS OF COMPANY SOURCES
OBSERVATION: the above molecules are those which are not yet launched in the Indian pharma
industry but are showing good growth in the international market and the company can make use
of these molecules in carrying out or launching new respiratory products in the Indian pharma
industry.
All the above molecules have been briefly explained in the previous page with their company, their
brand name, their indication, their category and also their date of approval by F.D.A (Food and
Drug Administration).
The rest molecules have not been taken into consideration because they are categorized in the
other segment that is the Cancer segment.
The molecule have only be taken for the year 2013.2012,2011,2010,2009 and 2008.


28 | P a g e

NEPHRO/URO SYSTEM

Nephrology is concerned with the treatment of kidney diseases, including hyper tension and
electrotype disturbances and also the people who require therapy including dialysis or renal
transplant. Most kidneys diseases are systematic disorders not limited to the organ but require
special treatment.
Function of Nephro system
EXCRETION OF WASTES: the kidney excrete waste products through the process
of metabolisim, which also includes UREA which is nitrogenous waste. The formation of
urine is also a function of the kidney. Exchange by vessels carrying the supply of blood to
the nephron is necessary for enabling this function.

REABSORPTION OF VITAL NUTRIENTS: Glucose at the normal plasma rate
is completely absorbed in the proximal tubule.the level of plasma will fully saturate the
transporters and glucose is lost in the urine.

ACID BASED HOMEOSTASIS: the kidney and the lungs are the two organ
systems that maintains the ph level around a relatively stable value. The kidneys have two
very important roles in maintaining the acid-base balance: to reabsorb bicarbonate from
urine,and to excrete hydrogen ions into urine.
Nephro means kidney in Greek. Nephrology is a
speciality of medicine that concerns with the study of
normal kidney function, problems related to kidney and
also the treatment of kidney function. A physician who
takes an additional training to become an expert in
nephrology are called as NEPHROLOGIST or a
RENAL PHYSICIAN.

29 | P a g e

OSMOLALITY REGULATION: an increase in osmolality that causes the glands
to secrete ADH, resulting in water reabsorption by kidney and increase in the concentration
of urine.

BLOOD PRESSURE REGULATION: the kidney cannot sense the blood directly
but the long-term regulation of the pressure of the blood is dependent on the kidney.


HORMONE SECRETION: The kidneys secrete a variety of hormones,
including erythropoietin, and the enzyme rennin. Erythropoietin is released in response
tohypoxia (low levels of oxygen at tissue level) in the renal circulation.



Observation: the above graph states that the diabetes share a very huge market of 43.8%
in kidney failure diseases and after the diabetes high blood pressure comes second in this
regard i.e 26.8%.

30 | P a g e

DISEASES OF NEPHRO SYSTEM
Acute and chronic kidney diseases: Most forms of kidney disease damage the
nephron ability to filter waste and fluid from the blood. As this unwanted material builds up
in the body, symptoms can include ankle swelling, fatigue, poor sleep, shortness of breath
and nausea. The final stage of kidney disease is kidney failure, a potentially fatal condition
in which the kidneys stop working altogether.
Cystic diseases of the kidney: Cystic kidney disease refers to a wide range
of hereditary, developmental, and acquired conditions.

With the inclusion of neoplasms
with cystic changes, over 40 classifications and subtypes have been identified. Depending
on the disease classification, the presentation of disease may be from birth, or much later
into adult life. Cystic disease may involve one or both kidneys and may or may not occur in
the presence of other anomalies. A higher incidence of cystic kidney disease is found in the
male population and prevalence increase with age.
Diabetes: Diabetes mellitus, or simply diabetes, is a group of metabolic diseases in
which a person has high blood sugar, either because the pancreas does not produce enough
insulin, or because cells do not respond to the insulin that is produced. This high blood
sugar produces the classical symptoms of polyuria (frequent urination), polydipsia
(increased thirst) and polyphagia.
Fluid and electrolyte disorders: A fluid or electrolyte disorder occurs
whenever there is an imbalance in the concentration of salts within the bloodstream. The
bloodstream and tissues have a specific concentration of water and natural salts important
to normal body function, which include sodium, potassium, calcium, bicarbonate, and
phosphate.
Glomerulonephritis and glomerular diseases: Glomerular disease
reduces the ability of the kidneys to maintain a balance of certain substances in
bloodstream.


31 | P a g e

Hypertension: Hypertension (HTN) or high blood pressure, sometimes called arterial
hypertension, is a chronic medical condition in which the blood pressure in the arteries is
elevated.This requires the heart to work harder than normal to circulate blood through the
blood vessels.
Kidney-related metabolic disorders: Metabolism is the sum of the chemical
processes and interconversions that take place in the cells and the fluids of the body. This
includes the absorption of nutrients and minerals, the breakdown and buildup of large
molecules, the interconversion of small molecules, and the production of energy from these
chemical reactions.
Kidney stones: A kidney stone, also known as a renal calculus is a
solid concretion or crystal aggregation formed in the kidneys from dietary minerals in
the urine.
Glomerular diseases: Glomerular disease reduces the ability of the kidneys to
maintain a balance of certain substances in bloodstream.
B.P.H (Benign prostatic hyperplasia): it is the increase in the size of the
prostate, it results in the formation of large,fairly discrete nodules in the prostate, it also
leads to the obstruction of the flow of urine. BPH does not lead to cancer or in any case
increase the risk of cancer. It also can be a major disease if it is lead untreated.




HYPERTENSION- A
CAUSE FOR
NEPHROLOGY

32 | P a g e

TREATMENT IN NEPHRO DISEASES

Treatment in nephrology are many which includes:
Medications as prescribed by the doctor: these include the medications which are needed to
cure the disease in case of nephrology diseases.

Surgical interventions: it includes the treatment in terms of surgery by removing or
replacing the organ.


Renal replacement therapy: this therapy is a term used which is used to encompass life
supporting treatments for renal failure. In context of chronic kidney disease, these treatment
does not cure chronic kidney disease. In certain acute conditions or injuries resulting in
failure, a person who likewise had a good response to dialysis, who got a kidney relatively
quickly if indicated- and whose body did not reject the transplanted compatible kidney and
who has no other significant health problems, could very well survive for many years.

Plasma exchange: the other name for plasma exchange is Plasmapheresis is the removal,
treatment, and return of (components of) blood plasma from blood circulation. It is thus
an extracorporeal therapy (a medical procedure performed outside the body). The method is
also used to collect plasma, which is frozen to preserve it for eventual use in the
manufacture of a variety of medications. The procedure is used to treat a variety of
disorders, including those of the immune system.

Kidney problems have a huge impact on length of the life, therefore, health education are the key
roles in nephrology. Chronic diseases of the kidney are critically managed through the treatment of
causative conditions like diabetes, avoidance of substances toxic to the kidney, anti-hyper tensives,
diet and weight modification and at last the planning for end stage renal failure.
Auto immune and inflammatory kidney disease can also be treated with immune suppression. The
commonly used agents under these are pre dnisolone, sirolimus, mycophenolate etc. the new
biological drugs are also used in these conditions. Most of the kidney or nephrology disease
problemare chronic in nature and they require long-term follow-up with the nephrologist which is
necessary.




33 | P a g e

STATE OF NEPHRO DISEASE IN INDIA
The exact prevalence of chronic kidney disease (CKD) is not clear however , the high
incidence of diabetes and heart disease in India indicate that CKD could be a silent
epidemic.

25-40% of all people with diabetes and heart disease develop chronic kidney disease.
Almost 50% of all CKD diseases occur due to diabetes and heart disease.

In an urban population study of 572,000 people ,incidence of End-stage-renal-disease
(ESRD) ranged from 151 to 232 cases per million population.

Diabetic nephropathy was the common cause of ESRD44%

One of the key challenges patients face in India is the exorbitant cost of therapy and
the availability of renal transplantation centers

It is estimated that India has approximately 100 approved centers, most of them in the private
sector.
In the absence of health insurance plans ,<10% of all patients have access to renal transplant
therapy.

Primary prevention measures focused on public education is critical at the patient and
primary physicians level. Secondary measures must be aimed at early diagnosis of CKD and
aggressive management.

Taking out all individuals that are above the age of 40 for blood sugar and hypertension is
crucial.
Taking out all diabetics and heart disease patients for an early stage CKD with creatinine
and micro albumin tests can save kidneys and prolong life.










34 | P a g e

FDA APPROVED DRUGS IN THERAPEUTIC AREA FOR
NEHROLOGY SEGMENT

These are the molecules which are not yet launched in the Indian pharma industry but have been
absorbed by the foreign pharma industry.
These are written year wise from 2013-2008
7. CYSTEAMINE BITARTRATE:
This molecule is used in the brand PROCYSBI which is ownwd by raptor pharmaceuticals
and is used for the management of nephropathic cystinosis, it is approved in may 2013
8. EVOROLIMUS:
This molecule is used in the brand product AFINITOR of novaritis and is used for the
treatment of renal angiomyolipoma associated with tuberous sclerosis complex, it was
approved in april 2012.
9. AXITINIB:
This molecule is used in the product INLYTA which is owned by Pfizer and is used for the
treatment of advanced renal cell carcinoma, it was approved in January 2012.
10. MIRABEGRON:
This molecule is used in the product MYRBETRIQ which is owned by astellas pharma
US,Inc.and is used for the treatment of overactive bladder. It was approved in june 2012.
11. PEGINESTADE:
This molecule is used in the product OMONTYS which is owned by affymax and is used
for the treatment of anemia due to chronic kidneydisease and was approved in march 2012.
12. AVANAFIL:
This molecule is used in the product STENDRA which is owned by vivus and is used for
the treatment of erectile dysfunction and was approved in april 2012.
13. REGORAFENIB:
This molecule is used in the product STIVARGA which is the brand of bayer healthcare
pharmaceuticals and is used for the treatment of previously treated patients with metastatic
colorectal cancer. And was approved in 2012.
14. GLUCARPIDASE:
This molecule is used in the product VORAXAZE which is the product of BTG
international and is used in the treatment of toxic plasma methotrexate concentrations in
patients with impaired renal function and was launched in 2012.
15. OXYBUTYNIN:
This molecule is used in ANTUROL GEL which is a product of antares pharma and is used
for the treatment of overactive bladder, it was approved in 2011.


35 | P a g e


16. BELATACEPT:
This molecule is used in NULOJIX which is a product of Bristol-myers squibb and is used
for the prevention of organ rejection following kidney transplant and was approved in june
2011.
17. ECULIZUMAB:
This molecule is used in SOLIRIS which is a product of alexion and is used for the
treatment of atypical hemolytic uremic syndrome and was approved in September 2011.
18. CABAZITAXEL:
This molecule is used in the product JEVTANA which is the brand product of sanofi
Aventis and is used for the treatment of prostate cancer, it was approved in 2010.
19. BEVACIZUMAB:
This molecule is used in the product AVASTIN which is a product of Genentech and is
used for the treatment of renal cell carcinoma, it is approved in july 2009.
20. FERUMOXITOL:
This molecule is used in the product FERAHENME which is owned by AMAG and is used
in the treatment of iron deficiency anemia associated with chronic kidney disease, it was
approved in june 2009.
21. PAZOPANIB:
This molecule is used in the product VOTREINT which is owned by glaxosmithklineand is
used for the treatment of renal cell carcinoma, it was approved in October 2009.

The following page will indicate the molecules that can be taken into consideration by the
company in order to adopt and also to grow in those molecules.











36 | P a g e


NAME INDICATION CATEGORY SALE (in Cr)

2010 2011 2012 2013
CYSTEAMINE
BITARTRATE
NEPHROPATHIC
CYSTINOSIS
CYSTEINE DEPLETING AGENT
NO MARKET, LAUNCHED IN MAY
2013
MIRABEGRON
URINARY
INCONTINENCE
BETA-3 RECEPTOR AGONIST` - 72 519 -
PEGINESTIDE
ANAEMIA
CHEMOTHERAPY
ERYTHROPOIESIS STIMULATING
AGENT
- - - 209
AVANAFIL
ERECTILE
DYSFUNCTION
PDE INHIBITOR - - 101 203
OXYBUTYNIN
URINARY
INCONTINENCE
ANTI-SPASMODIC 48 78 54 -
FERUMOXYTOL
IRON DEFICIENCY
ANAEMIA
FERAMOXYTILE 352 310 346 -

THE ABOVE DATA IS COLLECTED ON THE BASIS OF COMPANY SOURCES
OBSERVATION: the above molecules are those which are not yet launched in the Indian pharma
industry but are showing good growth in the international market and the company can make use
of these molecules in carrying out or launching new respiratory products in the Indian pharma
industry.
All the above molecules have been briefly explained in the previous page with their company, their
brand name, their indication, their category and also their date of approval by F.D.A (Food and
Drug Administration).
The rest molecules have not been taken into consideration because they are categorized in the
other segment that is the Cancer segment.
The molecule have only be taken for the year 2013.2012,2011,2010,2009 and 2008.


37 | P a g e












RESEARCH
METHODOLOGY










38 | P a g e

RESEARCH METHODOLOGY
FLOWCHART OF THE RESEARCH
THE RESEARCH HAS BEEN DIVIDED INTO 3 PARTS:
The first part comprises of the literature review which entails the understanding of the
subject and the problem based on the literature available .The first part also sees the data
collection of the company MANKIND PHARMA and also the introduction of the report.

In the second part the research design and type was defined.the research is a descriptive
research. The 3 softwares based on certain parameters were being taught in this regard and
the data was collected. however the use of secondary data is taken as the whole report is
secondary in nature.

Lastly the data would be analysed, statistical analysis will be doneand a solution to the
research problem would be derived and the study will be concluded.

METHODS OF DATA COLLECTION
The task of data collection begins after a research has been defined and the research/plan carved
out. A formal data collection process is necessary as it ensures that data gathered is both defined
and accurate and that subsequent decisions based on arguments embodied in the findings are valid.
The data used in the report is purely secondary in nature as it involves the use of 3 softwares:
1. IMS-HEALTH
2. PRESCRIPTION AUDIT
3. AIOCD.
Secondary data means the data that are already available. i.e. the data that is already been collected
and analaysed by someone else.while utilizing secondary data, various sources can be considered
from where it can be obtained like:
1.Books and Magazines 3.Upcoming softwares
2.Newspapers. 4.Public statistics,historical documents.



39 | P a g e

MARKET ANALYSIS OF RESPIRATORY SEGMENT
TOP COMPANIES IN RESPIRATORY SEGMENT


2013


2012


2011


Amt in crores

MAT-
RPS
GRWT
H-RPS
SHARE
-RPS
MAT-
RPS
GRWT
H-RPS
SHARE
-RPS
MAT-
RPS
GRWT
H-RPS
SHARE
-RPS

RESPIRATORY
SYSTEM
5098 6 100 4832 15 100 4193 11 100
CIPLA 928 7 18 870 12 18 776 12 19
ABBOTT* 376 7 7 352 30 7 270 -12 6
PFIZER* 329 8 6 304 18 6 259 10 6
ZYDUS
CADILA*
241 7 5 226 15 5 196 15 5
LUPIN
LIMITED
191 1 4 190 15 4 164 11 4

GLAXOSMITHK
LINE*
187 2 4 184 6 4 173 4 4
GLENMARK
PHARMA
170 24 3 137 23 3 111 33 3
WOCKHARDT
LTD*
147 1 3 146 22 3 120 16 3
CENTAUR 144 2 3 141 19 3 118 14 3
ALEMBIC 138 4 3 133 11 3 120 8 3

40 | P a g e


THE DATA IS CALCULATED WITH THE HELP OF IMS-HEALTH
SOFTWARE
Observation: It is observed that the top company in the respiratory segment is the CIPLA with
928 crores turnover but the growth of Glenmark pharma is at pace of 24 crores which is the highest
in comparison to all other top companies under this segment.

TOP COMPANIES WITH TOP TWO BRANDS IN
RESPIRATORY SEGMENT


2013 2012 2011
AMT. IN CRORES
MAT
-
RPS
GRWT
H-RPS
SHAR
E-RPS
MAT
-
RPS
GRWT
H-RPS
SHAR
E-RPS
MAT
-
RPS
GRWT
H-RPS
SHAR
E-RPS
RESPIRATORY
SYSTEM
519
0
7 100
485
3
14 100
423
9
10 100
CIPLA 969 11 19 874 11 18 784 11 19
ASTHALIN
CPL
135 0 3 135 5 3 128 2 3
FORACORT
CPL
113 14 2 99 19 2 83 23 2
ABBOTT* 381 8 7 353 32 7 269 -14 6
PHENSEDYL
COUGH A1H
244 11 5 220 38 5 160 -21 4
TOSSEX
A1H
35 1 1 35 34 1 26 -2 1
PFIZER* 332 8 6 307 18 6 260 8 6

41 | P a g e

COREX
PFZ
273 9 5 250 22 5 205 4 5
COREX-DX
PFZ
30 12 1 27 11 1 24 34 1
ZYDUS CADILA* 244 7 5 227 14 5 199 15 5
DERIPHYLLIN
G/R
73 2 1 71 9 1 66 6 2
FORMONIDE
G/R
37 11 1 33 16 1 29 5 1
LUPIN LIMITED 193 1 4 191 15 4 166 10 4
BUDAMATE
LU.
37 14 1 33 22 1 27 17 1
ESIFLO LU. 25 4 0 24 11 0 22 11 1
GLAXOSMITHKLI
NE*
188 3 4 183 5 4 175 5 4
CETZINE
GSK
46 2 1 45 8 1 42 6 1
PIRITON EXPECT
GSK
24 14 0 21 10 0 19 4 0
GLENMARK
PHARMA
174 25 3 139 22 3 114 35 3
ASCORIL +
GMK
66 7 1 61 11 1 55 28 1
ALEX PLUS
COUGH GMK
33 49 1 22 20 0 18 6 0

42 | P a g e

WOCKHARDT
LTD*
147 0 3 147 21 3 122 18 3
BRO-ZEDEX
WOK
49 2 1 48 21 1 40 30 1
ZEDEX
WOK
43 1 1 43 22 1 35 22 1
CENTAUR 146 3 3 141 18 3 120 14 3
SINAREST
CAU
89 -2 2 91 18 2 77 15 2
KOFAREST
CAU
11 7 0 11 10 0 10 10 0
ALEMBIC 140 5 3 133 10 3 121 7 3
WIKORYL
AMB
53 3 1 52 17 1 44 21 1
ZEET
AMB
28 7 1 26 -1 1 26 -2 1


THE DATA IS CALCULATED WITH THE HELP OF IMS-HEALTH
SOFTWARE
Observation:
It is noted that in cipla the brand forakort is growing with a satisfactory growth of 14 crores which
in turn has resulted in the top product of cipla in respiratory segment, whereas the piriton product
of glaxosmithkline company has shown a good growth of 14 crores in the current year, in glenmark
pharma the product alex plus cough has also shown a significant growth of 49 crores, zeet product
of alembric has also shown a positive growth of 7 crores in the current year.


43 | P a g e

TOP MOLECULES IN THE COUGH SECTOR OF
RESPIRATORY SEGMENT


2013 2012 2011

AMT. IN
CRORES
MAT-
RPS
GRWT
H-RPS
SHARE-
RPS
MAT-
RPS
GRW
TH-
RPS
SHA
RE-
RPS
MAT-
RPS
GRWT
H-RPS
SHAR
E-RPS
RESPIRATOR
Y SYSTEM
(TC1)
2431 5 100 2308 14 100 2025 8 100
COUGH AND
COLD
PREPARATIO
N (TC2)
2431 5 100 2308 14 100 2025 8 100
COUGH
PREPARATIO
NS
1846 5 76 1765 15 76 1541 7 76
COUGH PREP.
ETHICALS
1139 6 47 1071 10 46 977 11 48
CODEINE
AND COMB.
672 2 28 662 23 29 537 -1 27
ACETYLCYSTE
INE
22 22 1 18 34 1 13 33 1
COUGH PREP.
HOME
PRODS.
13 -3 1 13 1 1 13 -2 1

THE DATA IS CALCULATED WITH THE HELP OF IMS-HEALTH
SOFTWARE
Observation: In the given data it is noted that among the five cough molecules acetylcysteine
has a good growth of 22 crores and rest have D-growth in the current year 2013. Cough Prep.
Home Prods. Have a negative growth in 2011 as well as 2013, whereas, in 2012, it had a positive
growth of 1crore.

44 | P a g e

TOP MOLECULES IN ASTHMA SECTOR OF
RESPIRATORY SEGMENT


2013

2012

2011

AMT IN CRORES
MAT-
RPS
GROWT
H-RPS
SHARE
-RPS
MAT-
RPS
GROWT
H-RPS
SHARE
-RPS
MAT-
RPS
GROWT
H-RPS
SHARE
-RPS
RESPIRATORY
SYSTEM (TC1)
1828 9 100 1682 18 100 1428 14 100
ANTI-
ASTHMATICS(TC2)
1828 9 100 1682 18 100 1428 14 100
BRONCHODIL.INHALA
NT PREP. (TC3)
945 9 52 868 15 52 753 13 53
FORMOTERAL+BUDES
ONIDE(TC4)
215 16 12 186 23 11 151 19 11
SALMETEROL+FLUTIC
ASONE
170 5 9 162 8 10 151 10 11
SALBUTAMOL 105 -2 6 106 5 6 101 3 7
SALBUTAMOL+BECLO
METHASONE
94 -2 5 96 5 6 92 7 6
SALBUTAMOL+IPRATR
OPIUM
86 9 5 79 15 5 69 16 5
BUDESONIDE 81 14 4 71 22 4 58 18 4

45 | P a g e

FLUTICASONE +
FORMOTEROL
44 22 2 36 42 2 26 41 2
AZELASTINE +
FLUTICASONE
24 18 1 20 23 1 16 36 1
FORMOTEROL +
TIOTROPIUM
14 6 1 14 22 1 11 9 1
SALBUTAMOL+BUDES
ONIDE
11 7 1 10 23 1 8 24 1
FLUTICASONE 8 8 0 8 13 0 7 22 0
BRONCHODILATORS
SOLIDS(TC3)
645 10 35 585 25 35 468 16 33
LEVOCETIRIZINE+MON
TELUKAS
274 22 15 225 50 13 149 34 10
ETOPHYLLINE COMB. 52 4 3 50 10 3 45 6 3
DOXOFYLLINE SOLIDS 51 -13 3 58 7 3 54 14 4
MONTELUKAST 49 3 3 47 20 3 40 3 3
ACEBROPHYLLINE 40 19 2 34 36 2 25 80 2
THEOPHYLLINE 33 20 2 28 0 2 28 4 2

46 | P a g e

MONTELUKAST+FEXO
FENADINE
32 97 2 16 501 1 3 999 0
BAMBUTEROL+MONT
ELUKAST
15 -8 1 16 -8 1 18 4 1
MONTELUKAST+DOXO
FYLLINE
12 -3 1 13 140 1 5 554 0
ORCIPRENALINE &
COMB.
7 6 0 7 11 0 6 11 0
BROMHEXINE COMB. 2 9 0 2 14 0 2 40 0
MONTELUKAST
COMB.
1 270 0 0 999 0 0 0 0
BRONCHODILATORS
LIQUIDS(TC3)
136 -1 7 138 6 8 130 7 9
SALBUTAMOL COMB. 96 -3 5 98 6 6 93 5 6
SALBUTAMOL 15 17 1 13 4 1 12 1 1
AYURVEDIC 6 0 0 6 3 0 5 187 0
OTHER
COMB.BRONCHO.LIQ.
2 42 0 2 320 0 0 6 0
ACEBROPHYLLINE 2 26 0 2 4 0 2 87 0

47 | P a g e

THEOPHYLLINE COMB. 2 -17 0 2 2 0 2 -1 0
BROMHEXINE 1 7 0 1 19 0 1 -11 0
KETOTIFEN 1 -24 0 1 -12 0 1 5 0
CARBOCISTEINE 1 -19 0 1 -5 0 1 -12 0
TERBUTALINE COMB. 1 -30 0 1 -2 0 1 7 0
INHALER DEVICE(TC3) 39 8 2 36 16 2 31 21 2
INHALER DEVICE 39 8 2 36 16 2 31 21 2
BRONCHODILATORS,
OTHERS(TC3)
38 27 2 30 30 2 23 41 2
LEVOSALBUTAMOL 20 19 1 17 26 1 13 22 1
BRONCHODILATORS
LIQUIDS
18 35 1 13 35 1 10 78 1

48 | P a g e

BRONCHODILATORS
SOLIDS
0 144 0 0 -16 0 0 53 0
BRONCHODILATORS
INJECTA.(TC3)
22 -1 1 22 7 1 21 11 1
ETOPHYLLINE+THEOP
HYLLINE
20 0 1 20 6 1 19 10 1
DOXOFYLLINE
INJECTABLES
1 6 0 1 42 0 1 27 0
OTHER PLAIN
BRONCHO.INJ.
1 -5 0 1 10 0 1 23 0

THE DATA IS CALCULATED WITH THE HELP OF IMS-HEALTH
SOFTWARE
Observation:
The above data is based on the asthmatics molecules which are being used by the companies that
help in the related product formation, the molecules which have no market share have been deleted
in the above data and the rest molecules are being considered because of market share as well as
moving annual turnover.
FORMOTERAL+BUDESONIDE, ACEBROPHYLLINE, SALBUTAMOL, THEOPHYLLINE,
LEVOCETIRIZINE+MONTELUKAS, AZELASTINE + FLUTICASONE are the molecules
which have a significant growth and also have a positive market share rate.
These molecules can be used to produce a product in asthmatic segment as they have a very
positive relevance in the market.







49 | P a g e

MARKET ANALYSIS OF NEPHROLOGY SEGMENT
DRUGS FOR B.P.H (Benign Prostatic Hyperplasia)
DRUGS FOR BPH
AMOUNT IN
LAKHS
MAT-
RPS
GROWT
H-RPS
OCTOBER
NOVEMB
ER
DECEM
BER
JANUA
RY
FEBRU
ARY
MARC
H
DRUGS FOR BPH 27132 15 2360 2207 2288 2352 2200 2175
DUTASTERIDE +
TAMSULOSIN
9586 21 802 793 809 839 801 783
URIMAX-D
CPL
3411 19 285 291 298 303 281 277
VELTAM PLUS
IN9
1757 11 141 148 149 145 146 132
DUTAS-T
DRL
1093 28 89 82 84 100 105 107
GERIFLO-D
AMB
817 32 71 66 70 71 67 64
TAMSULOSIN 6899 9 595 549 569 584 531 539
URIMAX
CPL
3330 4 301 271 272 278 250 260
VELTAM
IN9
1233 6 102 98 103 105 96 94
CONTIFLO ICON
RBY
801 20 67 62 67 67 59 60

50 | P a g e

DYNAPRES
DRL
431 13 35 31 37 40 40 40
OTHER DRUGS
FOR BPH
4530 28 385 363 380 390 374 371
FLOTRAL
RBY
618 10 51 49 52 54 54 53
SILODAL
RBY
542 167 45 42 45 46 47 46
ALFOO
DRL
515 18 45 40 43 43 41 42
ALFUSIN-D
CPL
485 7 38 39 42 43 37 36
FINASTERIDE +
TAMSULOSIN
3883 7 387 331 335 340 307 292
URIMAX-F
CPL
1321 -5 113 107 114 113 102 98
VELTAM-F
IN9
1232 19 162 115 108 111 105 91
GERIFLO
AMB
617 11 53 50 51 54 46 48
FLOKIND-F
MA&
376 3 33 32 33 30 27 28
DUTASTERIDE 968 12 80 69 88 90 86 87

51 | P a g e



DUTAS
DRL
600 14 49 42 58 61 55 56
DUTAGEN
RBY
209 19 18 15 20 18 17 19
DUPROST
CPL
116 4 11 8 8 9 9 8
VELTRIDE
IN9
43 -10 2 3 3 3 4 3
FINASTERIDE 667 2 62 52 55 59 55 52
FINAST
DRL
534 4 50 43 41 45 44 43
FINCAR
CPL
111 -15 11 9 10 12 8 7
FISTIDE
S6T
6 -29 1 0 1 0 1 0
TOLTERODINE +
TAMSULOSIN
599 12 50 50 53 50 47 50
ROLIFLO
RBY
403 22 31 33 35 33 33 35
TAMLET
SPI
128 16 10 11 12 11 10 11
TOLTAM
IN9
40 -2 4 3 4 3 3 3

52 | P a g e

THE DATA IS CALCULATED WITH THE HELP OF IMS-HEALTH
SOFTWARE
Observation:
It is observed that in the above data the drugs for B.P.H has been taken out with the top companies
in each drug and also their moving annual total, their growth and also their monthly growth which
is unit wise.
Under this the geriflo brand has a good growth of 33 lakhs and ROLIFLO has a growth of 24 lakhs
as compared to other brands in the drug. Where in brands like BAPTER, TOLTAM, FISTIDE,
FINCAR, VELTRIDE, URIMAX etc. have a ve growth.
DUTAS-T has a good monthly report that is based on counting units.


















53 | P a g e

DRUGS FOR SEXUAL DISORDER

DRUGS FOR SEXUAL DISORDER
AMOUNT IN LAKHS
MAT-
RPS
GROWTH
-RPS
OCTO
BER
NOVEM
BER
DECEM
BER
JANU
ARY
FEBRU
ARY
MAR
CH
DRUGS FOR SEXUAL
DISORDER
34851 3 2705 3013 3236 3288 2977 2748
SILDENAFIL 21367 -4 1679 1917 1964 1961 1757 1657
MANFORCE
MA&
11736 -4 908 1072 1035 1059 949 931
PENEGRA
ZYC
2182 -8 173 190 212 228 175 162
CAVERTA RBY 2034 -3 157 179 179 187 175 166
VIAGRA PFZ 1564 -13 141 136 157 147 123 110
SEX STIMULANTS 5514 11 437 431 503 536 503 427
TENTEX FORTE
HIM
1042 49 74 75 100 102 95 78
ADDYZOA CH/ 1004 -2 85 77 84 89 88 79
CONFIDO HIM 762 24 58 56 65 68 71 58
SHILAJIT DBR 495 7 44 47 58 56 51 36
TADALAFIL 4179 8 319 368 393 394 362 341

54 | P a g e

MEGALIS MA5 2706 4 207 232 249 256 234 216
FORZEST RBY 664 2 50 60 71 64 61 57
TAZZLE DRL 508 18 41 41 46 50 43 43
PULMOPRES
CPL
135 48 10 11 11 12 11 12
DRUGS FOR ED 2972 100 200 231 300 327 292 265
TENTEX ROYAL
HIM
724 42 55 56 64 72 69 58
KUTUB X HT9 565 306 36 43 50 58 52 54
DA-SUTRA X
HT9
396 285 27 33 33 40 33 31
SUSTIMAX
EMU
256 7 8 23 30 26 24 25
DAPOXETINE 819 -29 70 67 75 70 64 59
SUSTINEX
EMU
340 -1 28 26 28 29 29 28
KUTUB HT9 84 -60 9 8 8 8 5 5
DURALAST SPI 63 -15 4 4 5 7 6 5
DA-SUTRA HT9 63 -57 6 7 9 6 4 3



55 | P a g e


THE DATA IS CALCULATED WITH THE HELP OF IMS-HEALTH
SOFTWARE
Observation:
It is noted that the drugs for E.D (erectile dysfunction) have shown a comparibily good growth
than rest of the drugs for sexual disorder that is around 39.80 lakhs of units in the year 2013 which
includes KUTUB X and DA-SUTRA X with very comfortable growth, wherein there monthly unit
wise growth is constant.
TENTEX ROYAL has a monthly high growth rate unit wise, whereas it can be noted that it will
have an increased growth in the coming years.



















56 | P a g e











CONCLUSION AND
RECOMMENDATIONS













57 | P a g e

CONCLUSION OF THE REPORT

A conclusion is mainly the end result of the report where the enyire analysis is being concluded. In this
report it has been found out that :
The respiratory segment in india is worth rupees 5211 crores out of which the Mankinds share is
around 50 crores. And the company ranks sixth in this sector.
After the whole data analysis the top molecules in the asthmatic sector of the respiratory segment
are:
FORMOTERAL+BUDESONIDE - Worth is 215 crores and growth is 16
LEVOCETIRIZINE+ MONTELUKAS worth is 27 crores and growth is 22
THEOPHYLLINE- worth is 33 crores and growth is 20
SALBUTAMOL worth is 15 crores and growth is 17
ACEBROPHYLLINE worh is 2 crores and gowth is 26
Under the respiratory segment there are some molecules which are being launched internationally
but are still to come in the Indian pharma market. however,these can be taken into consideration
by the MANKIND Pharma company to boost ther presence in the market. These molecules are:
BEDAQUILINE its worth is 280 crores
ROFLUMILAST its worth is 686 crores
CEFTAROLINE FOSAMIL its worth is 263 crores
TREPROSTINIL its worth is 1940 crores

The nephrology segment in india is worth rupees 320 crores out of which the mankinds share is
around 7 crores and the company ranks thirteen in this sector.
The top molecules in the nephro segment are:
DUTASTERIDE+TAMSULOSIN 96 crores and growth is 20.
TAMSULOSIN worth is 69 crores and growth is 9
DRUGS FOR E.D worth is 29 crores and growth is 100
SEX STIMULANTS worth is 55 crores and growth is 11
Under the nephrology segment there are some molecules which are being launched
internationally but are still to come in the Indian pharma market. however,these can be taken into
consideration by the MANKIND Pharma company to boost ther presence in the market. These
molecules are:
MIRABEGRON - Worth is 519 crores
PEGINESTIDE Worth is 209 crores
AVANAFIL Worth is 203 crores
OXYBUTYNIN Worth is 54 crores
FERUMOXYTOL Worth is 346 crores.



58 | P a g e

RECOMMENDATIONS

It is recommended that every company should make the use of the the analysis softwares
(I.M.S health, AIOCD, Prescription Audit ) so as to make the analysis part easy to calculate
and easy to interpret.
The molecules which have a good growth and also a good moving annual turnover could be
considered for further product development and product modification to make the branding
of the product more accelerating and having a good competitive advantage over other
products of the competitors.
The molecules which have been launched internationally but are still to be introduced in the
Indian pharma industry could be considered for new product development in the respiratory
segment and also nephro segment.
All the molecules which have a continous growth in the previous year and also have a
positive response from the prescriptions of doctors should be utilized more and good
marketing should be done in this regard.















59 | P a g e

REFERENCES
http://www.ddssafety.net/content/ways-prevent-colds-and-flu
http://archive.ispub.com/journal/the-internet-journal-of-epidemiology/volume-2-
number-2/respiratory-disease-burden-in-rural-india-a-review-from-multiple-data-
sources.html#sthash.qPotgMgP.dpbs
http://www.ddssafety.net/content/understanding-respiratory-illnesses
http://doctors-hospitals-medical-cape-town-south-
africa.blaauwberg.net/details.php?id=832
http://www.pamf.org/asthma/overview/facts.html
http://www.pharmabiz.com/NewsDetails.aspx?aid=73723&sid=2
http://www.medindia.net/health_statistics/health_facts/kidney-facts.html
http://www.centerwatch.com/drug-information/fda-approvals/drug-
areas.aspx?AreaID=18
http://www.webmd.com/drugs/condition-2383-
Erectile+Dysfunction.aspx?diseaseid=2383&diseasename=Erectile+Dysfunction
BOOK:
Essentials of medical pharmacology- 6
th
edition, K.D tripathy
UBM medica IDR triple-I vol.19
Company profile of mankind- (2012-2013)